There is a direct relationship between quality of life (QOL) and hemoglobin level for cancer patients, according to the results of a study published in the Aug.
15 issue of Cancer that correlated hemoglobin values with various QOL measures for cancer patients involved in community-based epoetin-alfa trials. “Hemoglobin increases have been associated with QOL improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin <10 g/dL,” write Jeffrey Crawford, MD, from Duke University Medical Center in Durham, North Carolina, and colleagues.
In two open-label, community-based trials of epoetin-alfa therapy that enrolled 4,382 anemic cancer patients undergoing chemotherapy, the investigators used the Linear Analog Scale Assessment (LASA) and the more detailed, disease-specific Functional Assessment of Cancer Therapy-Anemia (FACT-An) to determine the change in QOL associated with hemoglobin increases in 1 g/dL increments.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!